APA (7th ed.) Citation

AJ, Y., JP, L., EL, C., BC, L., O, N., RS, F., . . . NS, R. (2025). Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma. Blood advances, 9(5), 1163. https://doi.org/10.1182/bloodadvances.2024014717

Chicago Style (17th ed.) Citation

AJ, Yee, et al. "Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma." Blood Advances 9, no. 5 (2025): 1163. https://doi.org/10.1182/bloodadvances.2024014717.

MLA (9th ed.) Citation

AJ, Yee, et al. "Elotuzumab in Combination with Pomalidomide, Bortezomib, and Dexamethasone in Relapsed and Refractory Multiple Myeloma." Blood Advances, vol. 9, no. 5, 2025, p. 1163, https://doi.org/10.1182/bloodadvances.2024014717.